NASDAQ: RNXTRenovorx Inc Stock
$1.30-0.06 (-4.41%)
Updated Jun 13, 2025
RNXT Price
$1.30
Fair Value Price
$0.03
Market Cap
$47.54M
52 Week Low
$0.75
52 Week High
$1.69
P/E
-3.25x
P/B
3.61x
P/S
129.51x
PEG
N/A
Dividend Yield
N/A
Revenue
$240.00k
Earnings
-$10.16M
Gross Margin
60.8%
Operating Margin
-4,392.5%
Profit Margin
-4,232.5%
Debt to Equity
0.22
Operating Cash Flow
-$10M
Beta
0.87
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RNXT Overview
Renovorx Incorporated is a clinical-stage biopharmaceutical company developing treatments for solid tumor. The company's lead product is RenovoGem, a drug and device combination that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Renovorx was founded in 2009 and is headquartered in Los Altos, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RNXT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RNXT
Ranked#289 of 464
Ranked#289 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important RNXT news, forecast changes, insider trades & much more!
RNXT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RNXT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RNXT ($1.30) is overvalued by 3,955.37% relative to our estimate of its Fair Value price of $0.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RNXT ($1.30) is not significantly undervalued (3,955.37%) relative to our estimate of its Fair Value price of $0.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RNXT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RNXT due diligence checks available for Premium users.
Valuation
RNXT fair value
Fair Value of RNXT stock based on Discounted Cash Flow (DCF)
Price
$1.30
Fair Value
$0.03
Overvalued by
3,955.37%
RNXT ($1.30) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RNXT ($1.30) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RNXT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RNXT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.25x
Industry
-108.97x
Market
31.36x
RNXT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.61x
Industry
4.66x
RNXT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RNXT's financial health
Profit margin
Revenue
$197.0k
Net Income
-$2.4M
Profit Margin
-1,228.4%
RNXT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RNXT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$16.0M
Liabilities
$2.9M
Debt to equity
0.22
RNXT's short-term assets ($15.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RNXT's short-term assets ($15.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RNXT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
-$2.0k
Financing
$10.8M
RNXT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RNXT vs Biotech Stocks
Renovorx Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.